NACDS President and CEO Steven C. Anderson issued the following statement today following statements by the American Medical Association (AMA) regarding the Test to Treat Initiative for COVID antivirals that was mentioned by President Joe Biden and released by the Biden Administration last week.
“The AMA’s criticism of the role of pharmacy-based clinics in the new ‘test-to-treat’ COVID antivirals program is extremely unfortunate, but also extremely predictable.
“The effectiveness of COVID antivirals depends on patients’ receiving them shortly after the onset of symptoms. When it comes to the patient journey for these medications, access and equity are critically important, and pharmacy-based clinics, pharmacies and pharmacists have essential roles to play.
“As currently constructed, the ‘Test to Treat’ Initiative for COVID antivirals relies on traditional prescribers – including nurse practitioners and others in the pharmacy-based clinic setting. It relies on pharmacists to dispense the medications, as is appropriate given their extensive education and qualifications. If anything, the patient journey for these medications would benefit further from the inclusion of pharmacists as prescribers, consistent with the Ninth Amendment to the current declaration of the Public Readiness and Emergency Preparedness Act, or PREP Act.
“The AMA’s criticism of pharmacy-based clinics in the prescribing function, and by extension pharmacists in the dispensing function, seems to continue a ‘just say no’ approach. Up to this point in the pandemic, the AMA has lobbied against pharmacist-provided COVID testing and has questioned pharmacist-provided COVID vaccinations. Nonetheless, pharmacies, pharmacists and pharmacy teams have contributed to the effectiveness, equity, accessibility and convenience of the pandemic response on behalf of the American people. According to government statistics, pharmacies provide more than 2 of every 3 COVID vaccine doses. More than 30 percent of children ages 5 to 11 who have received their COVID vaccination have done so at a pharmacy. Half of pharmacy COVID vaccination sites are located in areas with high social vulnerability, and 70 percent of pharmacy testing sites are in areas with moderate to severe social vulnerability. The access provided by pharmacies – the face of neighborhood healthcare – is sorely needed; it in no way replaces physicians but rather provides access that is otherwise impossible in the healthcare delivery system today.
“Regarding COVID antivirals, a Morning Consult poll commissioned by NACDS found that a majority of adults support pharmacists offering COVID antiviral medications and prescribing the medications. Respondents gave pharmacies the highest ratings for ease of access among healthcare destinations tested. Among entities working to address COVID, only hospitals received a higher rating than pharmacies. That is not to say that policymaking should be pursued with polls; yet it should take into account the proven ability of healthcare professionals and access points to meet the needs of Americans with trust, convenience, reliability and equity.”
EDITOR’S NOTE:
Of related interest is a March 9, 2022, opinion piece in MEDPAGE TODAY, authored by Amesh Adalja, MD, senior scholar, Johns Hopkins Center for Health Security, practicing infectious disease, critical care, and emergency physician in Pittsburgh, March 9, 2022. In a piece titled “A Successful ‘Test-to-Treat’ Program Requires All Hands on Deck,” Dr. Adalja states: “We can’t have a guild-like mentality that seeks to use government force to exclude qualified persons from engaging in a field for which the AMA wants physicians to be the exclusive purveyors.”
